The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Vertex Pharmaceuticals Inc

Nasdaq: VRTX
Last

(U.S.) $133.50

Today's change-2.03 -1.50%
Updated June 23 4:00 PM EDT. Delayed by at least 15 minutes.
 

Vertex Pharmaceuticals Inc

Nasdaq: VRTX
Last

(U.S.) $133.50

Today's change-2.03 -1.50%
Updated June 23 4:00 PM EDT. Delayed by at least 15 minutes.

Vertex Pharmaceuticals Inc down (U.S.)$2.03

Vertex Pharmaceuticals Inc closed lower Friday, dropping (U.S.)$2.03 or 1.50% to (U.S.)$133.50. Over the last five days, shares have gained 8.41% and are currently 2.74% off of the 52-week high. Shares have outperformed the S&P 500 by 35.98% during the last year.

Key company metrics

  • Open(U.S.) $136.58
  • Previous close(U.S.) $135.53
  • High(U.S.) $137.00
  • Low(U.S.) $132.12
  • Bid / Ask(U.S.) $123.90 / (U.S.) $134.09
  • YTD % change+81.21%
  • Volume2,172,643
  • Average volume (10-day)2,059,803
  • Average volume (1-month)1,903,992
  • Average volume (3-month)1,921,795
  • 52-week range(U.S.) $71.46 to (U.S.) $137.26
  • Beta1.75
  • Trailing P/E188.54×
  • P/E 1 year forward80.31×
  • Forward PEG1.31×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $0.71
Updated June 23 4:00 PM EDT. Delayed by at least 15 minutes.

Latest Company News

View more News

Latest Press Releases

View more Press Releases
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2017Q4/2016Q3/2016Q2/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016
Revenue715459414432
Total other revenue--------
Total revenue715459414432
Gross profit668399361387
Total cost of revenue46605344
Total operating expense444419433428
Selling / general / administrative113110106112
Research & development274248272271
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)10000
Other operating expenses, total1111
Operating income27140-193
Interest income (expense), net non-operating-17------
Gain (loss) on sale of assets--------
Other--------
Income before tax25420-39-18
Income after tax25028-40-36
Income tax, total4-7118
Net income24833-39-65
Total adjustments to net income--------
Net income before extra. items24833-39-65
Minority interest-251-28
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items24833-39-65
Inc. avail. to common incl. extra. items24833-39-65
Diluted net income24833-39-65
Dilution adjustment--------
Diluted weighted average shares249245245244
Diluted EPS excluding extraordinary itemsvalue per share1.000.13-0.16-0.26
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share1.040.13-0.16-0.26